Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.52 |
| ▸ | TTR | P02766 | 2/20 | 0.46 |
| ▸ | ALB | P02768 | 2/20 | 0.46 |
| ▸ | GRM5 | P41594 | 3/20 | 0.41 |
| ▸ | XDH | P47989 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | SELL | P14151 | 1/20 | 0.36 |
| ▸ | SELP | P16109 | 1/20 | 0.36 |
| ▸ | SELE | P16581 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL501406 | 0.94 | ALDH1A1 (0.52) | ALDH1A1CYP2A6TTRALBGRM5 | |
| SCHEMBL3258882 | 0.87 | ALDH1A1 (0.42) | ALDH1A1CYP2A6TTRALBGRM5 | |
| SCHEMBL16962561 | 0.87 | ALDH1A1 (0.42) | ALDH1A1CYP2A6TTRALBGRM5 | |
| SCHEMBL18934332 | 0.87 | ALDH1A1 (0.42) | ALDH1A1CYP2A6TTRALBGRM5 | |
| SCHEMBL22477339 | 0.83 | CYP2A6 (0.39) | ALDH1A1CYP2A6TTRALBGRM5 | |
| SCHEMBL10204233 | 0.83 | ALDH1A1 (0.39) | ALDH1A1CYP2A6TTRALBGRM5 | |
| SCHEMBL60145 | 0.83 | TTR (0.50) | ALDH1A1CYP2A6TTRALBMEN1 | |
| SCHEMBL6741465 | 0.82 | ALDH1A1 (0.42) | ALDH1A1CYP2A6TTRALBGRM5 | |
| SCHEMBL2160734 | 0.82 | ALDH1A1 (0.42) | ALDH1A1CYP2A6TTRALBGRM5 | |
| SCHEMBL255241 | 0.82 | GRM5 (0.45) | ALDH1A1CYP2A6TTRALBGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 520 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116375549-A | Method and system for synthesizing amide compound from nitrile compound | 深圳湾实验室 | 2023-07-04 | — | — | CN | claimed |
| EP-3337655-B1 | METHODS FOR RETREADING TIRES EMPLOYING CUSHION GUM WITH STABLE DINITRILE OXIDE CURE SYSTEM | BRIDGESTONE AMERICAS TIRE OPERATIONS LLC (US) | 2020-09-23 | — | — | EP | claimed |
| EP-2529388-B1 | FRAGMENTATION REAGENTS FOR MASS SPECTROMETRY | MICROMASS LTD (GB) | 2019-10-23 | — | — | EP | claimed |
| US-20130122599-A1 | Fragmentation Reagents For Mass Spectrometry | MICROMASS UK LIMITED (GB) | 2013-05-16 | — | — | US | claimed |
| EP-1841802-B1 | THIN WALLED POLYNITRILE OXIDE CROSSLINKED RUBBER FILM PRODUCTS AND METHODS OF MANUFACTURE THEREOF | I FLOW CORP (US) | 2011-06-08 | — | — | EP | claimed |
| US-12590062-B2 | PD-1/PD-L1 inhibitors | GILEAD SCIENCES, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| US-20260062443-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMA INC (US) | 2026-03-05 | — | — | US | disclosed |
| CN-120092029-A | Resin composition, cured product, prepreg, metal foil-clad laminate, resin composite sheet, and printed wiring board | 三菱瓦斯化学株式会社 | 2025-06-03 | — | — | CN | disclosed |
| CN-114787120-B | Compound and method for producing same, resin composition, resin sheet, multilayer printed wiring board, and semiconductor device | 三菱瓦斯化学株式会社 | 2024-08-09 | — | — | CN | disclosed |
| US-12048238-B2 | Organometallic compound and organic light-emitting device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2024-07-23 | — | — | US | disclosed |
| US-20240244950-A1 | ORGANIC LIGHT-EMITTING DEVICE AND ELECTRONIC APPARATUS INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2024-07-18 | — | — | US | disclosed |
| US-20240244870-A1 | LIGHT-EMITTING DEVICE, ELECTRONIC DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2024-07-18 | — | — | US | disclosed |
| EP-0995761-A2 | Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders | Dupont Pharmaceuticals Company (US) | 2000-04-26 | — | — | EP | disclosed |
| US-6022523-A | NOVEL CYCLIC COMPOUNDS CONTAINING CARBOCYCLIC AND HETEROCYCLIC RING SYSTEMS | DUPONT PHARMACEUTICALS COMPANY (US) | 2000-02-08 | — | — | US | disclosed |
| US-5879657-A | Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1999-03-09 | — | — | US | disclosed |
| EP-0692982-A4 | RADIOLABELED PLATELET GPIIb/IIIa RECEPTOR ANTAGONISTS AS IMAGING AGENTS FOR THE DIAGNOSIS OF THROMBOEMBOLIC DISORDERS | DU PONT MERCK PHARMA (US) | 1998-03-11 | — | — | EP | disclosed |
| CN-1122577-A | Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders | DU PONT MERCK PHARMA (US) | 1996-05-15 | — | — | CN | disclosed |
| EP-0692982-A1 | RADIOLABELED PLATELET GPIIb/IIIa RECEPTOR ANTAGONISTS AS IMAGING AGENTS FOR THE DIAGNOSIS OF THROMBOEMBOLIC DISORDERS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-01-24 | — | — | EP | disclosed |
| WO-1994022494-A1 | RADIOLABELED PLATELET GPIIb/IIIa RECEPTOR ANTAGONISTS AS IMAGING AGENTS FOR THE DIAGNOSIS OF THROMBOEMBOLIC DISORDERS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-10-13 | — | — | WO | disclosed |
| EP-0052437-A1 | Antibacterial compounds, processes for their preparation and compositions containing them | BEECHAM GROUP PLC (GB) | 1982-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062443-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | C9, SSB, C1S | ALDH1A1 3835/4885CYP2A6 3871/4885TTR 193/4885 |
| US-12048238-B2 | Organometallic compound and organic light-emitting device including the same | TRPC1, PPOX, LAGE3 | ALDH1A1 654/4885CYP2A6 4557/4885TTR 3131/4885 |
| US-20240244950-A1 | ORGANIC LIGHT-EMITTING DEVICE AND ELECTRONIC APPARATUS INCLUDING THE SAME | EML4, DNMT3L, LIN28A | ALDH1A1 818/4885CYP2A6 2799/4885TTR 3281/4885 |
| US-12590062-B2 | PD-1/PD-L1 inhibitors | CD274, PDCD1LG2, PDCD1 | ALDH1A1 409/4885CYP2A6 1049/4885TTR 2913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.